AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
2026-06-22 11:24:51
AbbVie Inc. agreed to buy Apogee Therapeutics Inc. for $10.9 billion in cash, one of its largest deals in recent years, to bolster its anti-inflammatory portfolio amid growing competition for its best-selling drug, according to Bloomberg.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
